COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019–Associated Hospitalization Surveillance Network, March 1–June 30, 2020

Abstract Using a coronavirus disease 2019 (COVID-19)–associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1–June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased. Using data collected from a national surveillance network for COVID-19-associated hospitalizations, we describe inpatient COVID-19 investigational treatment use from March-June, 2020. Overall, hydroxychloroquine, azithromycin and remdesivir were used frequently. Over time, use of hydroxychloroquine and azithromycin declined, while remdesivir increased.